NCT01133405COMPLETEDanonymous

Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

Sponsor

Source record

Eli Lilly and Company

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

LY2886721 targets the inhibition of gamma-secretase, an enzyme involved in the cleavage of amyloid precursor protein (APP), which is implicated in the pathogenesis of Alzheimer's Disease.

Indication / condition

AI-normalized

Alzheimer's Disease

Intervention

Source record

LY2886721, Placebo

Related intelligence directories

Indication directory: Alzheimer's Disease Modality directory: small molecule Target directory: LY2886721 targets the inhibition of gamma-secretase

Source & freshness

Source record

NCT ID

NCT01133405

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jul 17, 2026

Internal sync

Jul 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01133405

Title

Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

Sponsor

Eli Lilly and Company

Status

COMPLETED

Phase

Phase 1

Condition raw

Alzheimer's Disease

Condition normalized

Alzheimer's Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

LY2886721 targets the inhibition of gamma-secretase, an enzyme involved in the cleavage of amyloid precursor protein (APP), which is implicated in the pathogenesis of Alzheimer's Disease.

Target normalized

LY2886721 targets the inhibition of gamma-secretase, an enzyme involved in the cleavage of amyloid precursor protein (APP), which is implicated in the pathogenesis of Alzheimer's Disease.

Interventions

LY2886721, Placebo

Public preview

Source record

LY2886721, developed by Eli Lilly and Company, is positioned within the competitive landscape of Alzheimer's Disease therapeutics, targeting a critical mechanism associated with amyloid beta production. The completion of this Phase 1 study indicates progress towards understanding the safety and pharmacokinetics of LY2886721, which may enhance Eli Lilly's portfolio in a market characterized by high unmet needs and significant competition from other amyloid-targeting therapies. The results could inform future development strategies and potential partnerships, as well as influence investor sentiment regarding Eli Lilly's pipeline in neurodegenerative diseases.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jul 28, 2026

Report code

NCT01133405-Jul 28, 2026

NCT ID

NCT01133405

Status

COMPLETED

Phase

Phase 1

Sponsor

Eli Lilly and Company

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJul 17, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01133405

Indication

Alzheimer's Disease

Modality

small molecule

Target

LY2886721 targets the inhibition of gamma-secretase, an enzyme involved in the cleavage of amyloid precursor protein (APP), which is implicated in the pathogenesis of Alzheimer's Disease.

Intervention

LY2886721, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.